What To Know
- “The acquisition demonstrates our commitment to the growing biopharma market and to providing more comprehensive solutions to some of the world’s most complex challenges in therapy and vaccine development.
- “The acquisition of Masterflex extends Avantor’s single-use offering and gives us a complete end-to-end solution for aseptic fluid transfer throughout the bioproduction workflow,”.
Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, has completed its previously announced acquisition of the Masterflex bioprocessing business and related assets (collectively “Masterflex”) of Antylia Scientific, a privately held, portfolio company of investment firms GTCR and Golden Gate Capital.
“The acquisition of Masterflex extends Avantor’s single-use offering and gives us a complete end-to-end solution for aseptic fluid transfer throughout the bioproduction workflow,” said Michael Stubblefield, President and CEO of Avantor. “The acquisition demonstrates our commitment to the growing biopharma market and to providing more comprehensive solutions to some of the world’s most complex challenges in therapy and vaccine development. We welcome Masterflex associates to the Avantor team and look forward to working together.”
Based in Illinois, Masterflex is a leading global manufacturer of peristaltic pumps and aseptic single-use fluid transfer technologies. The acquisition strengthens Avantor’s offering across all bioproduction platforms including monoclonal antibodies (mAbs), cell and gene therapy and mRNA, and supports both therapy and vaccine manufacturing including COVID-19.
The completion of the acquisition follows the receipt of all applicable regulatory approvals.